Barclays
AURA icon

Barclays’s Aura Biosciences AURA Stock Holding History

Barclays’s Portfolio AURA Stock Details AURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$103K Buy
14,462
+2,922
+25% +$20.9K ﹤0.01% 4032
2026
Q1 		$77.2K Sell
11,540
-57,758
-83% -$331K ﹤0.01% 4141
2025
Q4 		$378K Buy
69,298
+4,366
+7% +$25.9K ﹤0.01% 4011
2025
Q3 		$401K Sell
64,932
-3,619
-5% -$23.7K ﹤0.01% 3939
2025
Q2 		$429K Buy
68,551
+18,156
+36% +$106K ﹤0.01% 3842
2025
Q1 		$295K Sell
50,395
-22,330
-31% -$169K ﹤0.01% 3836
2024
Q4 		$598K Buy
72,725
+11,715
+19% +$110K ﹤0.01% 3716
2024
Q3 		$544K Buy
61,010
+43,897
+257% +$376K ﹤0.01% 3724
2024
Q2 		$129K Sell
17,113
-8,281
-33% -$60.7K ﹤0.01% 3787
2024
Q1 		$199K Sell
25,394
-12,775
-33% -$106K ﹤0.01% 4121
2023
Q4 		$338K Buy
38,169
+33,295
+683% +$282K ﹤0.01% 4128
2023
Q3 		$43.7K Sell
4,874
-22,978
-83% -$247K ﹤0.01% 3924
2023
Q2 		$344K Sell
27,852
-6,565
-19% -$70.2K ﹤0.01% 2975
2023
Q1 		$319K Sell
34,417
-2,102
-6% -$21.8K ﹤0.01% 3546
2022
Q4 		$383K Sell
36,519
-5,525
-13% -$70.3K ﹤0.01% 3475
2022
Q3 		$762K Sell
42,044
-142
-0.3% -$2.15K ﹤0.01% 2417
2022
Q2 		$598K Sell
42,186
-17,511
-29% -$290K ﹤0.01% 2742
2022
Q1 		$1.31M Buy
+59,697
New +$1.14M ﹤0.01% 2191

Other funds holding AURA

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Barclays's AURA Position: Q2 2026 in Review

Barclays increased its Aura Biosciences (AURA) stake by 25% in Q2 2026, buying an estimated $20.9K and bringing the position to 14,462 shares worth $103K. The position accounts for ﹤0.01% of the portfolio, ranked #4032.

Barclays first reported a position in AURA in Q1 2022 and has held it in 18 quarters since. The position peaked at $1.31M in Q1 2022. 146 funds tracked by Wall St. Rank hold AURA as of Q2 2026.

  • Barclays held 14,462 shares of Aura Biosciences worth $103K as of Q2 2026.
  • Barclays bought 2,922 Aura Biosciences shares in Q2 2026, an estimated $20.9K.
  • Aura Biosciences made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4032 holding.
  • Barclays first reported a position in Aura Biosciences in Q1 2022 and has held it in 18 quarters since.
  • Barclays's Aura Biosciences position peaked at $1.31M in Q1 2022.
  • 146 funds tracked by Wall St. Rank held Aura Biosciences as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.